Abstracts tagged "Biomarkers"

Abstract Number: 2362 • ACR Convergence 2023
Identification of Protein Biomarkers Associated with the Severity and Risk of Progression of Interstitial Lung Disease in VEDOSS and Established Systemic Sclerosis Patients
Thierry Sornasse¹, Vishal Kakkar², Rebecca Ross³, Sunhwa Kim⁴ and Francesco Del Galdo⁵, ¹AbbVie, Inc., North Chicago, IL, ²University of Leeds, Leeds, United Kingdom, ³Medicine and Health, University of Leeds, Leeds, United Kingdom, ⁴AbbVie, Inc., South San Francisco, CA, ⁵University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom
Background/Purpose: Pulmonary Fibrosis (PF) is one of the primary causes of systemic sclerosis (SSc)-related death. Hence, monitoring and predicting the course of PF in SSc…
Abstract Number: 2539 • ACR Convergence 2023
Baseline IL-10 Levels as a Predictive Biomarker for Achieving Clinical Response with Abatacept in ACPA+ Patients with Early RA
Jinqi Liu¹, Yicong Li², Kai Fu¹, Chun Wu¹, Peter Schafer³, Sean Connolly¹, Ian M. Catlett⁴, Michael Maldonado¹, Robert Wong⁵, Paul Emery⁶, Yoshiya Tanaka⁷, Vivian Bykerk⁸, Clifton Bingham⁹, Thomas Huizinga¹⁰ and Roy Fleischmann¹¹, ¹Bristol Myers Squibb, Princeton, NJ, ²Parexel International, Durham, NC, ³Bristol Myers Squibb, Belle Mead, NJ, ⁴Bristol Myers Squibb, Pennington, NJ, ⁵Bristol Myers Squibb (at the time of analysis), Princeton, NJ, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷University of Occupational and Environmental Health, Kitakyushu, Japan, ⁸Department of Rheumatology, Hospital for Special Surgery, New York, NY, ⁹Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹Division of Rheumatology, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: A key target of RA treatment is to achieve early and sustained remission in order to ensure lower levels of long-term structural joint damage…
Abstract Number: 0064 • ACR Convergence 2023
Correlation of Anti-DFS70 Autoantibodies by ELISA with HEp-2 Cells DFS Pattern by IFA
Vincent ricchiuti¹, Michael Nappi², Kelly Chun², Ajay Grover¹ and Rubio Punzalan², ¹Labcorp, Dublin, OH, ²Labcorp, Calabasas, CA
Background/Purpose: The discovery and characterization of the dense fine speckled (DFS, ICAP AC-2) nuclear pattern of antinuclear autoantibodies (ANA) detected in HEp-2 cells by indirect…
Abstract Number: 0440 • ACR Convergence 2023
Baseline T Cell and B Cell-related Markers and HLA-DRB1 Shared Epitope Alleles Predict the Therapeutic Efficacy of Abatacept in Patients with Moderate to Severe Rheumatoid Arthritis
Ting Wang¹, Natalia V. Giltiay², Christian Lood² and Bobby Kwanghoon Han², ¹University of Washington, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Abatacept, a CTLA-4-Ig fusion protein, is widely used as a treatment for rheumatoid arthritis (RA). However, data on predictive biomarkers associated with therapeutic response…
Abstract Number: 0589 • ACR Convergence 2023
A Comparative Evaluation of IgA2 Anti-dsDNA Antibodies and Clinical Outcome in Two Clinical Trials of Belimumab After Rituximab in SLE
Muhammad RA Shipa¹, Daniel McCluskey¹, Laura Cooney² and Michael Ehrenstein¹, ¹University College London, London, United Kingdom, ²Immune Tolerance Network, Seattle, WA
Background/Purpose: We have shown that serum IgA2 anti-dsDNA antibody levels is a biomarker of response to belimumab after rituximab in SLE (BEAT-lupus trial) (1). We…
Abstract Number: 0847 • ACR Convergence 2023
Development of an IFN 5-Gene Signature Score to Identify IFN-high and IFN-low Subsets and as a Pharmacodynamic Biomarker for Deucravacitinib Treatment in a Phase 2 Trial in Patients with Systemic Lupus Erythematosus
Chun Wu¹, Yanhua Hu¹, Mary K. Crow², Amit Saxena³, Cristina Arriens⁴, Coburn Hobar¹, Adrian Coles⁵ and Ian M. Catlett⁶, ¹Bristol Myers Squibb, Princeton, NJ, ²Hospital for Special Surgery, New York, NY, ³NYU Langone, New York, NY, ⁴Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK, ⁵Bristol Myers Squibb, Lawrenceville, NJ, ⁶Bristol Myers Squibb, Pennington, NJ
Background/Purpose: Elevated IFN activity is observed in a subset of lupus subjects suggesting that those with higher levels of IRGs may benefit from interferon targeted…
Abstract Number: 1134 • ACR Convergence 2023
Pilot Study Investigating Adenosine Deaminase-2 as a Disease Activity Biomarker for Cardiac Sarcoidosis
Jeffrey Shen¹, Jayanth Doss¹, Ravichandra Karra Gurunath¹, Kelly Arps¹, Megan Milne², Rishi Rampersad¹, Kees Frelinger¹, Michael Hershfield¹ and Teresa Tarrant¹, ¹Duke University, Durham, NC, ²Costal Carolina Health Care, New Bern, NC
Background/Purpose: Sarcoidosis is a heterogenous granulomatous inflammatory disease that is especially dangerous when it affects the heart where it may cause fatal arrythmias and heart…
Abstract Number: 1339 • ACR Convergence 2023
Neutrophil Activation and Formation of Neutrophil Extracellular Traps Are Associated with Response to Abatacept in Patients with Moderate to Severe Rheumatoid Arthritis
Ting Wang¹, Natalia V. Giltiay², Christian Lood² and Bobby Kwanghoon Han², ¹University of Washington, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Neutrophil activation and formation of neutrophil extracellular traps (NETs) have been implicated in the pathogenesis of rheumatoid arthritis (RA). Calprotectin, a neutrophil activation marker,…
Abstract Number: 1643 • ACR Convergence 2023
Exploring the Serum Metabolome for Potential Diagnostic Markers of Psoriatic Arthritis
Nikita Looby¹, Max Kotlyar², Chiara Pastrello², Darshini Ganatra¹, Vathany Kulasingam³, Igor Jurisica⁴ and Vinod Chandran⁵, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Osteoarthritis Research Program, Division of Orthopaedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic diseases, Krembil Research Institute, Toronto, ON, Canada, ³Department of Laboratory Medicine and Pathobiology, University of Toronto and Division of Clinical Biochemistry, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute and Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, ⁵Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory immune-mediated musculoskeletal skin disease that affects approximately 25% of psoriasis patients causing progressive disability. As a heterogeneous disease,…
Abstract Number: 1792 • ACR Convergence 2023
Identifying Synovial Fluid Micro-RNA Signature That Distinguishes Psoriatic Arthritis from Osteoarthritis
Darshini Ganatra¹, Anas Samman¹, David Nasri¹, Sara Rahmati¹, Omar Cruz Correa¹, Rohan Machhar¹, Rajiv Gandhi², Mohit Kapoor³ and Vinod Chandran⁴, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Orthopaedics, Department of Surgery, University of Toronto, Toronto, ON, Canada, ³Schroeder Arthritis Institute, University Health Network and Department of Surgery, University of Toronto, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic Arthritis (PsA) is an inflammatory arthritis and shares several clinical features with Osteoarthritis (OA), the most common form of arthritis. This often leads…
Abstract Number: 2221 • ACR Convergence 2023
Clinical and Molecular Patterns Associated with Persistence of Inflammation in Spondyloarthritis Patients: Unveiling Potential Biomarkers
Lourdes Ladehesa Pineda¹, Ivan Arias de la Rosa², Laura Cuesta-López³, Clementina López Medina⁴, María Ángeles Puche Larrubia⁵, Miriam Ruiz-Ponce³, María del carmen Ábalos Aguilera³, Pedro Ortiz Buitrago³, Yasin Hanaee³, Carlos Perez-Sanchez⁶, Chary López-Pedrera³, Alejandro Escudero-Contreras⁷, Eduardo Collantes Estévez⁸ and Nuria Barbarroja⁹, ¹Rheumatology Department Reina Sofia Universitary Hospital, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba. Rheumatology service. Cordoba. Spain, Cordoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁴Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain, ⁵Department of Rheumatology, Reina Sofia University Hospital, Cordoba, Spain, ⁶IMIBIC, Córdoba, Spain, ⁷Rheumatology Department, Reina Sofia University Hospital, Cordoba/Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Córdoba, Spain, ⁸Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Cordoba, Spain, ⁹University of Cordoba, Córdoba, Spain
Background/Purpose: Chronic inflammation is closely associated with an increased risk of cardiovascular diseases (CVD) through the activation of the immune system and the release of…
Abstract Number: 2364 • ACR Convergence 2023
Circulating CTHRC1 Levels Are Associated with Disease Severity and Predict Survival in Systemic Sclerosis
Monica Yang¹, Seoyeon Lee², Lisa Hazelwood³, Dean Sheppard¹, Francesco Boin⁴ and Paul Wolters¹, ¹University of California San Francisco, San Francisco, CA, ²Yale University School of Medicine, New Haven, CT, ³AbbVie, Inc., North Chicago, IL, ⁴Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Despite recent advances in systemic sclerosis (SSc), there remains a paucity of clinically actionable biomarkers to assess disease severity and predict progression. Collagen triple…
Abstract Number: 2572 • ACR Convergence 2023
Autoantibody Profile of Autoimmune Driven Interstitial Lung Disease as Compared to Idiopathic Pulmonary Fibrosis and Association of Autoantibodies with Survival
Elena Joerns¹, Chad Newton², Stanislav Kolenikov³, Jeffrey Sparks⁴ and David Karp⁵, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²UT Southwestern, Dallas, TX, ³NORC at the University of Chicago, Columbia, MO, ⁴Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁵UT Southwestern Medical Center, Dallas, TX
Background/Purpose: The term interstitial pneumonia with autoimmune features (IPAF) describes patients with interstitial lung disease (ILD) and features of autoimmunity, that do not fulfill classification…
Abstract Number: 0090 • ACR Convergence 2023
Reduced Frequency of RORγt+ Regulatory T Cells Is Associated with Secukinumab Response in Axial Spondyloarthritis
Addison Pacheco¹, Michael Tang¹, Sinead Maguire², Melissa Lim¹, Fataneh Tavasolian³, Zoya Qaiyum⁴ and Robert Inman¹, ¹University Health Network, Toronto, ON, Canada, ²Toronto Western Hospital, Toronto, ON, Canada, ³Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Axial spondyloarthritis (AxSpA) is an inflammatory disease that predominantly affects the spine and the sacroiliac joints. Dysregulation of Type 3 immunity has been implicated…
Abstract Number: 0503 • ACR Convergence 2023
Spinal Inflammation a Dominant Pathology in Psoriatic Arthritis: Characterization and Quantification by In-Vivo 18F-FDG Total-Body PET/CT Imaging
Siba Raychaudhuri¹, Yasser Abdelhafez², Dario Mazza², Smriti K Raychaudhuri³ and Abhijit Chaudhari⁴, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ²University of California Davis, Sacramento, CA, ³VA Sacramento Medical Center, Mather, CA, ⁴UC Davis School of Medicine, Sacramento, CA
Background/Purpose: Right and Moll recognized the presence of spinal inflammation/axial disease in psoriatic arthritis (PsA) in their seminal work in 1973. The prevalence of axial…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].